GALIMEDIX THERAPEUTICS

galimedix-therapeutics-logo

Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments.

#Website #More

GALIMEDIX THERAPEUTICS

Industry:
Pharmaceutical Therapeutics

Address:
Kensington, Maryland, United States

Country:
United States

Website Url:
http://www.galimedix.com

Total Employee:
1+

Status:
Active

Contact:
972-4-9905139

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache


Official Site Inspections

http://www.galimedix.com

  • Host name: mi3-ts107.a2hosting.com
  • IP address: 66.198.240.20
  • Location: Ann Arbor United States
  • Latitude: 42.2503
  • Longitude: -83.8393
  • Metro Code: 505
  • Timezone: America/Detroit
  • Postal: 48106

Loading ...

More informations about "Galimedix Therapeutics"

About us โ€“ Galimedix Therapeutics

Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated โ€ฆSee details»

Galimedix Therapeutics

At Galimedix, we are working to improve the lives of millions of patients worldwide by developing game-changing drugs to treat major neurodegenerative diseases where amyloid beta plays a โ€ฆSee details»

Galimedix Therapeutics - Crunchbase Company Profile & Funding

Galimedix Therapeutics is located in Kensington, Maryland, United States. Who invested in Galimedix Therapeutics? Galimedix Therapeutics is funded by InFocus Capital Partners. โ€ฆSee details»

Galimedix Therapeutics, Inc. - LinkedIn

Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to ...See details»

Contact โ€“ Galimedix Therapeutics

Email: [email protected]. Fields marked with an * are required. Name * Company Email * Telephone Message * Mailing List PLEASE CHECK here if you would like to be added to our โ€ฆSee details»

Galimedix - LifeScienceHistory.com

Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. โ€ฆSee details»

Galimedix Therapeutics GmbH - Innovations- und Gründerzentrum ...

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and โ€ฆSee details»

Galimedix Therapeutics, Inc. - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Galimedix Therapeutics, Inc. of Kensington, MD. Get the latest business insights from Dun & Bradstreet.See details»

Galimedix Therapeutics - Funding, Financials, Valuation & Investors

Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments. New. Resources. Advanced Search. Start Free Trial . ... How much โ€ฆSee details»

Galimedix Therapeutics - VentureRadar

Galimedix is a clinical stage pharmaceutical and ophthalmic company developing transformative treatments based on a novel mechanism of action directed to the common cause for several โ€ฆSee details»

Galimedix Therapeutics - PitchBook

Galimedix Therapeutics is headquartered in Kensington, MD. What is the size of Galimedix Therapeutics? Galimedix Therapeutics has 9 total employees. What industry is Galimedix โ€ฆSee details»

Galimedix Therapeutics, Inc. (Galimedix Therapeutics, Inc.) - ่ฏ็‰ฉ็ฎก โ€ฆ

Galimedix holds global rights to GAL-201. About Galimedix Therapeutics, Inc. Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective โ€ฆSee details»

Théa and Galimedix enter into Licensing Agreement | Théa

Galimedix will grant TOI exclusive rights for the development and commercialization of GAL-101, Galimedixโ€™s lead disease-modifying compound, for the topical and oral treatment of dry age โ€ฆSee details»

Galimedix GmbH Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Galimedix GmbH of Planegg, Bayern. Get the latest business insights from Dun & Bradstreet.See details»

Partnering โ€“ Galimedix Therapeutics

Galimedix received an upfront technology access fee and is eligible to receive further success-based milestone payments as well as royalties on net sales. While TOI will fully fund the โ€ฆSee details»

Galimedix Therapeutics, Inc. - GoingPublic.de

Galimedix is a Phase 2 clinical-stage private biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious โ€ฆSee details»

Galimedix Therapeutics initiates Phase 1 study with oral small โ€ฆ

Dec 5, 2024 Kensington, MD, USA, December 5, 2024 โ€“ Galimedix Therapeutics, Inc. (โ€œGalimedixโ€), a Phase 2 clinical-stage biotechnology company developing novel oral and โ€ฆSee details»

Galimedix Therapeutics GmbH - Innovations- und Gründerzentrum ...

Galimedix verfolgt das Ziel, neurodegenerative Prozesse an ihrem Ursprung zu stoppen und entwickelt bahnbrechende neuroprotektive Therapien zur Behandlung schwerer Augen- und โ€ฆSee details»

BIO-Europe: Galimedix is developing amyloid beta aggregation โ€ฆ

Nov 5, 2024 BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aฮฒ upstream of where most others have focused - the lead programs are in โ€ฆSee details»

Métis Nation of Ontario claims vindication while critics dismiss โ€ฆ

1 day ago The Métis Nation of Ontario is claiming vindication after a much-anticipated report supported the presence of seven Métis communities in the province, while opponents are โ€ฆSee details»